Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers

Video

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.

There are currently phase III studies evaluating pembrolizumab in head and neck cancer both in combination with in comparison to cytotoxic chemotherapies. The goal of these trials is to move pembrolizumab into an earlier line, said Bauml.

While pembrolizumab has significantly less toxicities than cytotoxic chemotherapies, the key difference between the two therapies is that pembrolizumab produces much more durable responses, said Bauml.

Related Videos
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD